Cyclo

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Research, Exercise, Science, Patent, Alzheimer's disease, Patient, NPC, Therapy, CYTH, FDA, Cyclo, Pharmaceutical industry

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.
  • “Following the completion of the merger with Applied Molecular Transport, we are poised to continue building momentum and achieving the value-driving milestones ahead.
  • Net loss for the year ended December 31, 2023 was approximately $20.1 million.
  • The changes in research and development expenses resulted from the increased activity in the Company’s Phase 3 study of Trappsol® Cyclo™ for the treatment of NPC.

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Retrieved on: 
Monday, December 18, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lung, Brain, Safety, Spleen, Senior, Business development, Food, Therapy, NPC1, Liver, Priority review, NPC, Patient, CYTH, Trial of the century, DSM-IV codes, Standard of care, Cyclo, SOC, Cell, Pharmaceutical industry

N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, added, “We view our Type C meeting with FDA as a catalytic and transformational milestone for our ongoing pivotal Phase 3 NPC program.

Key Points: 
  • N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, added, “We view our Type C meeting with FDA as a catalytic and transformational milestone for our ongoing pivotal Phase 3 NPC program.
  • For more information about the Company’s TransportNPC™ pivotal Phase 3 study, visit www.ClinicalTrials.gov and reference identifier NCT04860960 .
  • Cyclo Therapeutics received Orphan Drug Designation for Trappsol® Cyclo™ to treat NPC1 in both the U.S. and EU and Fast Track and Rare Pediatric Disease Designations in the U.S.
  • The Rare Pediatric Disease Designation is one of the chief requirements for sponsors to receive a Priority Review Voucher in the U.S. upon marketing authorization.

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Balance sheet, Therapy, Exercise, Private placement, NPC, Patient, CYTH, Science, AMTI, Cyclo, Pharmaceutical industry, Security (finance)

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023.
  • “Our number one priority remains to be the solid operational execution of our TransportNPC™ study.
  • We remain hopeful that we will bring enrollment for this important study to a close in the coming months,” commented N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics.
  • “Further, during the quarter we entered into a strategic merger agreement with Applied Molecular Transport, which we expect to close before year end.

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Pharmaceutical, Health, Science, Good Company (company), CYTH, Exercise, NPC, Phase, Niemann–Pick disease, type C, Therapy, Patient, Security (finance), Management, Cyclo

The New Warrants will be exercisable for cash only and have a term of four years from the issuance date.

Key Points: 
  • The New Warrants will be exercisable for cash only and have a term of four years from the issuance date.
  • The Investors include Rafael Holdings, Inc., a significant shareholder of the Company, several directors of the Company, Company management, and their affiliates.
  • N. Scott Fine, CEO of Cyclo Therapeutics, commented, “We continue to navigate through difficult market conditions with the best interest of our shareholders in the near and long term as a priority.
  • The Offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (“Securities Act”).

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq – NX

Retrieved on: 
Tuesday, October 3, 2023
Intercept, NextGen Healthcare, Agreement, Tripura Merger Agreement, Brodsky, CYTH, Thoma Bravo, CSCO, Splunk, Therapy, Cyclo, Security (finance), Holding company, AMT, Cisco

BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- BALA CYNWYD, October 3, 2023 /Globe Newswire/ -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- BALA CYNWYD, October 3, 2023 /Globe Newswire/ -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, Intercept will be acquired by Alfasigma S.p.A (“Alfasigma”) for $19.00 per share in cash for each share of Intercept held.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq – NX

Retrieved on: 
Tuesday, September 26, 2023
Intercept, NextGen Healthcare, Agreement, Tripura Merger Agreement, Brodsky, CYTH, Thoma Bravo, CSCO, Splunk, Therapy, Cyclo, Security (finance), Holding company, AMT, Cisco

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, Intercept will be acquired by Alfasigma S.p.A (“Alfasigma”) for $19.00 per share in cash for each share of Intercept held.
  • Under the terms of the Agreement, AMT will be acquired by Cyclo Therapeutics, Inc. (“Cyclo Therapeutics”) (Nasdaq - CYTH) in an all-stock transaction.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPLK, CYTH, AMTI

Retrieved on: 
Sunday, September 24, 2023
Cyclo(18)carbon, Fraud, Advertising, Sale, Cisco, Security (finance), Sulfur, Splunk, Cyclo

If you are a Splunk shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Splunk shareholder, click here to learn more about your rights and options .
  • If you are an Applied Molecular shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq – NXGN), Computer Task Group, Incorporated (Nasdaq -

Retrieved on: 
Thursday, September 21, 2023
Agreement, NextGen Healthcare, Tripura Merger Agreement, Brodsky, CYTH, CTG, Thoma Bravo, CSCO, Splunk, Therapy, Cyclo, Security (finance), AMT, Cisco

BALA CYNWYD, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the Agreement, AMT will be acquired by Cyclo Therapeutics, Inc. (“Cyclo Therapeutics”) (Nasdaq - CYTH) in an all-stock transaction.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

AMTI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Applied Molecular Transport Inc. Is Fair to Shareholders

Retrieved on: 
Thursday, September 21, 2023
Class Action Lawsuit, Professional Services, Legal, Cyclo(18)carbon, Fraud, AMTI, Advertising, Sale, Security (finance), Cyclo

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Molecular Transport Inc. (NASDAQ: AMTI) to Cyclo Therapeutics, Inc. for 0.174 shares of Cyclo for each share of Applied Molecular is fair to Applied Molecular shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Molecular Transport Inc. (NASDAQ: AMTI) to Cyclo Therapeutics, Inc. for 0.174 shares of Cyclo for each share of Applied Molecular is fair to Applied Molecular shareholders.
  • The investigation concerns whether Applied Molecular and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Applied Molecular shareholders; (2) determine whether Cyclo is underpaying for Applied Molecular; and (3) disclose all material information necessary for Applied Molecular shareholders to adequately assess and value the merger consideration.
  • On behalf of Applied Molecular shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Retrieved on: 
Thursday, September 21, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Tripura Merger Agreement, CYTH, DSM-IV codes, Mergers and acquisitions, AMT, Patient, NPC, Therapy, AMTI, Pharmaceutical industry, NPC1, Cyclo

Following the closing of the Merger, the combined company will operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH”.

Key Points: 
  • Following the closing of the Merger, the combined company will operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH”.
  • The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1).
  • “We are extremely pleased to enter into this merger agreement with Applied Molecular Transport,” commented N. Scott Fine, CEO of Cyclo Therapeutics.
  • Cyclo Therapeutics has continued to demonstrate its commitment to developing life-changing medicines and execution across clinical and regulatory fronts.